BreastPub Date : 2025-02-01DOI: 10.1016/j.breast.2025.103904
D. Alexandrou, M. Papakonstantinou, G. Kolympa, V.N Papadopoulos
{"title":"P012: 5-year vs 10-year Hormone Therapy: Comparison of Recurrence in Patients with Luminal A and Luminal B Breast Cancer","authors":"D. Alexandrou, M. Papakonstantinou, G. Kolympa, V.N Papadopoulos","doi":"10.1016/j.breast.2025.103904","DOIUrl":"10.1016/j.breast.2025.103904","url":null,"abstract":"","PeriodicalId":9093,"journal":{"name":"Breast","volume":"80 ","pages":"Article 103904"},"PeriodicalIF":5.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143576777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BreastPub Date : 2025-02-01DOI: 10.1016/j.breast.2025.103912
H. Yao, M. Yan, Z. Tong, X. Wu, Y. Yin, M.-H. Ryu, J.J. Park, T. Dai, Y. Zhao, J.H. Kim, S. Wang, Y. Zhong, M. Voskoboynik, J. Zhang, A. Kaubisch, C. Liu, Y. Chen, S.-A. Im, L. Wu, Y. Liu, E Song
{"title":"P024: Updated efficacy and safety of SHR-A1811, an anti-HER2 antibodydrug conjugate, in heavily pretreated advanced solid tumors with HER2-expression or mutations: a global, multicenter, phase 1 study","authors":"H. Yao, M. Yan, Z. Tong, X. Wu, Y. Yin, M.-H. Ryu, J.J. Park, T. Dai, Y. Zhao, J.H. Kim, S. Wang, Y. Zhong, M. Voskoboynik, J. Zhang, A. Kaubisch, C. Liu, Y. Chen, S.-A. Im, L. Wu, Y. Liu, E Song","doi":"10.1016/j.breast.2025.103912","DOIUrl":"10.1016/j.breast.2025.103912","url":null,"abstract":"","PeriodicalId":9093,"journal":{"name":"Breast","volume":"80 ","pages":"Article 103912"},"PeriodicalIF":5.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143576827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BreastPub Date : 2025-02-01DOI: 10.1016/j.breast.2025.103898
K. Hudson, W. Gathirua-Mwangi, Z.L. Cui, M. Richey, B. Grimes, J. Wang, A.M Liepa, E. Brechtelsbauer, R. Volodarsky, K. Moreira, H Soliman
{"title":"P004: Clinical Characteristics and Treatment Persistence in US Patients with HR+/HER2-, Node Positive Early Breast Cancer Treated with Abemaciclib: Real-World Study from First Year After Approval","authors":"K. Hudson, W. Gathirua-Mwangi, Z.L. Cui, M. Richey, B. Grimes, J. Wang, A.M Liepa, E. Brechtelsbauer, R. Volodarsky, K. Moreira, H Soliman","doi":"10.1016/j.breast.2025.103898","DOIUrl":"10.1016/j.breast.2025.103898","url":null,"abstract":"","PeriodicalId":9093,"journal":{"name":"Breast","volume":"80 ","pages":"Article 103898"},"PeriodicalIF":5.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143576928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BreastPub Date : 2025-02-01DOI: 10.1016/j.breast.2024.103863
L. Foffano , L. Cucciniello , E. Nicolò , I. Migliaccio , C. Noto , C. Reduzzi , L. Malorni , M. Cristofanilli , L. Gerratana , F. Puglisi
{"title":"Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i): Mechanisms of resistance and where to find them","authors":"L. Foffano , L. Cucciniello , E. Nicolò , I. Migliaccio , C. Noto , C. Reduzzi , L. Malorni , M. Cristofanilli , L. Gerratana , F. Puglisi","doi":"10.1016/j.breast.2024.103863","DOIUrl":"10.1016/j.breast.2024.103863","url":null,"abstract":"<div><div>CDK4/6 inhibitors (CDK4/6i) have significantly impacted on the treatment of HR + HER2 negative (HER2-) metastatic breast cancer (BC) when combined with endocrine therapy. Nonetheless, despite significant research efforts, the mechanisms of de novo and acquired resistance to CDK4/6i have not yet been fully elucidated, highlighting the need for a deeper understanding of these process. Additionally, the importance of dissecting CDK4/6i resistance from endocrine resistance for personalized treatment is increasingly recognized.</div><div>Liquid biopsy has emerged as a minimally invasive tool for identifying circulating biomarkers of resistance through the integration of multiparametric and dynamic assessments that encompass ctDNA, CTCs, exosomes, and epigenetic ctDNA alterations, representing a promising perspective for the clinical characterization of treatment resistance and guiding post-progression strategies to improve patient outcomes.</div><div>Aim of this review is summarize potential mechanisms of CDK4/6i resistance, along with the advantages of using liquid biopsy to identify resistance biomarkers in HR+/HER2- MBC patients treated with CDK 4/6 inhibitors.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"79 ","pages":"Article 103863"},"PeriodicalIF":5.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142881109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BreastPub Date : 2025-02-01DOI: 10.1016/j.breast.2024.103869
Megan Chua Wern Ee , Ashley Lee Shi Hui , Wong Hung Chew , Emmeline Elaine Cua-Delos Santos , Sean Li Siwei , Sng Ming Xian , Qin Xiang Ng , Serene Goh Si Ning
{"title":"Oncological outcomes following extreme oncoplastic breast conserving surgery (eOPBCS) for locally advanced breast cancer (LABC): A systematic review and meta-analysis","authors":"Megan Chua Wern Ee , Ashley Lee Shi Hui , Wong Hung Chew , Emmeline Elaine Cua-Delos Santos , Sean Li Siwei , Sng Ming Xian , Qin Xiang Ng , Serene Goh Si Ning","doi":"10.1016/j.breast.2024.103869","DOIUrl":"10.1016/j.breast.2024.103869","url":null,"abstract":"<div><h3>Introduction</h3><div>Locally advanced breast cancer (LABC) accounts for 5 % of new breast cancer diagnoses in developed countries and 30–60 % in developing regions. Historically, treatment relied on mastectomy guided by the Halstedian theory. Advances in neoadjuvant chemotherapy (NACT), breast-conserving surgery (BCS), and radiation have transformed treatment into a multimodal approach. Extreme oncoplastic BCS (eOPBCS) has expanded the boundaries of BCS, enabling large-volume resections with breast reshaping. However, its oncologic outcomes compared to mastectomy remain unclear, particularly in LABC.</div></div><div><h3>Methods</h3><div>A systematic review and meta-analysis were conducted following PRISMA guidelines (PROSPERO: CRD42024535182). Studies involving eOPBCS for LABC were reviewed, and those comparing outcomes with mastectomy were included in the meta-analysis. The primary outcomes were overall survival (OS), disease-free survival (DFS), and local recurrence rates (LRR). Data were synthesized using a random-effects model.</div></div><div><h3>Results</h3><div>Of 866 identified studies, 33 were included in the systematic review and 4 in the meta-analysis, involving 2902 patients with LABC. Among them, 16.1 % underwent eOPBCS. Patients receiving eOPBCS were younger, had larger tumours, and more frequently underwent axillary clearance. The pooled hazard ratio (HR) for OS comparing mastectomy to eOPBCS was 1.72 (95% CI 1.04-2.83). Meanwhile, HRs for DFS (1.11, 95% CI 0.60-2.08) and LRR (0.67, 95% CI 0.38-1.18) showed that there were no statistically significant differences but a trend toward lower recurrence rates with mastectomy.</div></div><div><h3>Conclusion</h3><div>eOPBCS demonstrates comparable to superior oncological outcomes to mastectomy in LABC, offering a promising option for selected patients. However, slightly elevated local recurrence rates, though not statistically significant, highlight the importance of careful patient selection and further research. High-quality prospective studies are essential to validate these findings and refine criteria for incorporating eOPBCS into routine clinical practice.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"79 ","pages":"Article 103869"},"PeriodicalIF":5.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142969566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}